45 results about "Cathepsin L" patented technology

The present invention relates to a method for treating tissue damage caused by ischemia in a patient which comprises administering to said patient a therapeutically effective amount of a compound which is an inhibitor of cathepsin B or cathepsin L, but which is not as an effective inhibitor of calpain relative to cathepsin B or cathepsin L or both and which compound is a peptidyl diazomethyl ketone.

This invention is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin K or cathepsin L, will be therapeutically useful.

The invention relates to the field of medicinal chemistry, particularly to a cathepsin inhibitor, a preparation method and applications thereof, more particularly to a tumor-associated cathepsin L inhibitor and a tumor-associated cathepsin D inhibitor, and a preparation method of the tumor-associated cathepsin L inhibitor and the tumor-associated cathepsin D inhibitor. Specifically the present invention further relates to a novel peptoid compound or a pharmaceutically acceptable salt thereof, a solvate, a pharmaceutical composition and a pharmaceutical preparation, a preparation method of thecompound, and applications of the peptoid compound or the pharmaceutically acceptable salt thereof, the solvate, the pharmaceutical composition and the pharmaceutical preparation in preparation of antitumor drugs, wherein the structure formula of the compound is defined in the specification, and R1, R2 are defined in the claims and the specification. The formula (I) is defined in the specification.

The invention discloses an anti-human Legumain protein monoclonal antibody, a hybridoma cell strain LGMN-2 and applications thereof. The name of provided hybridoma cell strain is LGMN-2, and the preservation number is CGMCC No.12995. The provided anti-human Legumain protein monoclonal antibody is secreted by the hybridoma cell strain LGMN-2 with a preservation number of CGMCC No.12995. The provided monoclonal antibody has a high titer, and the maximal indirect method titer can reach 1:2.56*10<8>. There is no cross reaction between the monoclonal antibody and Legumain proteins: Cathepsin B, Cathepsin H, and Cathepsin L; and the specificity is good.

The present invention discloses a new application of compound solidarum spray extract dry powder in pharmacy. The present invention finds that compound solidarum spray extract dry powder at 1 mg / mL can inhibit the new coronavirus drug target Cathepsin L protease by 55.6%. ; the inhibition rate of HIV protease is IC 50 =0.38mg / mL can be used alone or in combination with other drugs for the prevention and treatment of new coronavirus pneumonia drugs and antiviral drugs.

The invention relates to a hydrazinonitrile cathepsin K inhibitor, and an application thereof in preparation of osteoarthritis treatment drugs, and belongs to the technical field of cathepsin inhibitors. The inhibitor contains a novel P3 group with different orientations, has a nano-mole concentration level inhibition effect on cathepsin K outside cells, has hundreds-of-times or above selectivity to cathepsin K, cathepsin S and cathepsin B, and also has hundreds-of-times or above selectivity to highly homologous cathepsin K and cathepsin L. Culture is carried out under the following two conditions: (1) cell passage and (2) ascorbic acid and beta-glycerophosphoric acid stimulation with primary chondrocytes as a model. Results of gelatin zymography and quantitative fluorescence assay tests show that the expression level of the cathepsin K under every one of the above two conditions is increased; and the activity of the cathepsin K is reduced after the novel inhibitor is added. The inhibitor also has a good inhibition effect in the cells, and has a very good inhibition effect on the cathepsin K.

The invention relates to a protein marker for sicca syndrome in saliva and application of the protein marker. Particularly, the invention relates to application of a protein identification reagent inpreparation of a reagent for diagnosing the sicca syndrome in a subject. Protin is selected from a combination of acylamino acid release enzyme, 1,4-glucose formyl transfer enzyme, Calumenin, C-C motif chemotatic factor ligand 28, activation-induced cytidine deaminase, alpha collagen 1 chain, carboxypeptidase D, carboxypeptidase E, cysteine proteinase inhibitor C, cathepsin L, DnaJ heat shock protein family (Hsp40) member C3, furan paired basic amino acid lyase, HtrA serine peptidase 1, kallikrein correlated peptidase 11, trypsin 3, proteasome subunit-4, proteasome subunit 9, antichymotrypsinand vimentin.

The invention relates to a method for extracting freshwater fish dorsal muscle myosin, which belongs to the technical field of aquatic products. The steps of the method of the present invention are as follows: first put the live fish into a turnover box equipped with fresh water and let it stand for 1 to 2 hours; quickly take the dorsal muscle of the live fish; rinse the diced fish with ice water; rinse with buffer solution; finally prepare Obtain myosin solution. The present invention obtains higher-purity fish myosin by eliminating the influence of cathepsin L when extracting domestic fish dorsal muscle myosin.

Human cathepsin L inhibitors and probes containing a vinyl sulfonate ester moiety are described. The inhibitors are highly potent (low nM affinity), selective, and cell permeable, and can inhibit ultra-low concentration of active cathepsin L. The developed probes are highly sensitive and can detect an ultra-low amount of probe-labeled active cathespin L.

The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and / or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.

A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.